VACCINE POTENTIAL OF MENINGOCOCCAL FRPB - STUDIES ON SURFACE EXPOSUREAND FUNCTIONAL ATTRIBUTES OF COMMON EPITOPES

Citation
Da. Alaaldeen et al., VACCINE POTENTIAL OF MENINGOCOCCAL FRPB - STUDIES ON SURFACE EXPOSUREAND FUNCTIONAL ATTRIBUTES OF COMMON EPITOPES, Vaccine, 12(6), 1994, pp. 535-541
Citations number
31
Categorie Soggetti
Immunology
Journal title
ISSN journal
0264410X
Volume
12
Issue
6
Year of publication
1994
Pages
535 - 541
Database
ISI
SICI code
0264-410X(1994)12:6<535:VPOMF->2.0.ZU;2-4
Abstract
Neisseria meningitidis expresses several novel outer membrane proteins (OMPs) in vivo and when grown under iron limitation in vitro. One of the most prominent is a 70 kDa ken-regulated protein (FrpB). FrpB was purified by elution from SDS-polyacrylamide gels and rabbit polyclonal antiserum (R-70) was raised against it. R-70 was bactericidal against homologous, but not heterologous, strains in the presence of human co mplement. The bactericidal activity was retained when R-70 was adsorbe d with formaldehyde-fixed iron-replete cells (i.e. not expressing FrpB ), but lost when adsorbed with fixed iron-restricted cells (which expr ess FrpB). A murine monoclonal anti-FrpB antibody (mAb M70) was raised against a common epitope which showed complete cross-reaction on West ern blots of OMPs from other serogroups and serotypes of N. meningitid is and some commensal Neisseriae species. However, it failed to kill t he organism. Immunogold electron microscopy on ultrathin sections, usi ng the R-70 antiserum adsorbed with fixed iron-replete cells, showed l abelling on 40% of the cells, whereas the R-70 adsorbed with fixed iro n-restricted cells and mAb M70 failed to label. However, none of these sera labelled whole cells, suggesting lack of surface accessibility. It appears that the highly conserved cross-reactive epitopes of FrpB o nly become exposed in the process of generating the antigen, whereas t he surface-exposed epitopes recognized in killing assays are immunolog ically variable among different strains. Therefore, despite the strong immunogenicity of the common epitopes of FrpB in vivo, their apparent lack of surface exposure and the failure of antibodies against them t o kill meningococci do not support consideration of this protein alone as the sole component of a broadly cross-protective vaccine.